Physician profile
Mark A Paden
NPI 1336288133
$1,446.64
in general payments reported to CMS, 2019-2025
14 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $183 · 2022: $77.61 · 2023: $101 · 2024: $602 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $835.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $512.42 | 2024 | Persona, Rosa |
| Smith+Nephew, INC. | $222.60 | 2019 | |
| Stryker Corporation | $197.44 | 2019-2024 | Aequalis Ascend Flex, Blueprint Patient Specific Instrumentation |
| Pylant Medical | $133.92 | 2020 | |
| Depuy Synthes Sales INC. | $127.36 | 2022-2025 | Monovisc, Vapr, Truespan Orthocord |
| Medtronic, INC. | $61.03 | 2025 | Aquamantys(Tm) |
| Horizon Therapeutics Plc | $42.05 | 2019 | |
| Convatec INC. | $29.94 | 2023 | |
| Medtronic USA, INC. | $27.65 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $22.75 | 2025 | |
| Zimvie INC. | $18.61 | 2023 | |
| Pacira Therapeutics, INC. | $17.66 | 2019 | |
| Bioventus LLC | $17.56 | 2025 | Durolane |
| Heron Therapeutics, INC. | $15.65 | 2025 | Zynrelef |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Paden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.